1 active not recruiting, 1 recruiting, 1 unknown. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Recruiting 1, Unknown 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Other Cancer: new trials by email Literature Review of Other Cancer trials Research Report on Other Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) rezatapopt, pembrolizumab - Advanced Solid Tumor, Advanced Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | PMV Pharmaceuticals, Inc | 300 | 2020-10-29 | 2026-10-02 |
| The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy Erlotinib, Trastuzumab, Trastuzumab emtansine - Breast Cancer, Gastrointestinal Cancer | Phase 2 | Unknown | Fondazione per la Medicina Personalizzata | 400 | 2020-10-07 | 2023-10-03 |
| Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT) ruxolitinib - Other Cancer | Phase 2 | Active not recruiting | Massachusetts General Hospital | 50 | 2019-04-19 | 2025-11-10 |
Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Gallbladder Neoplasms (1) · Gastrointestinal Neoplasms (1) · Head and Neck Neoplasms (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1) · Prostatic Neoplasms (1) · Small Cell Lung Carcinoma (1) · Triple Negative Breast Neoplasms (1)
Breast Diseases (2) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Gastrointestinal Diseases (2) · Lung Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2) · Thoracic Neoplasms (2) · Adnexal Diseases (1)
Ado-Trastuzumab Emtansine (1) · Alpelisib (1) · Erlotinib Hydrochloride (1) · Everolimus (1) · Ipilimumab (1) · Lapatinib (1) · Nivolumab (1) · Trastuzumab (1) · Vemurafenib (1) · alectinib (1) · atezolizumab (1) · brigatinib (1) · cobimetinib (1) · entrectinib (1) · ipatasertib (1)
Fondazione per la Medicina Personalizzata (1) · Massachusetts General Hospital (1) · PMV Pharmaceuticals, Inc (1)
Italy (2) · United States (2) · Australia (1) · France (1) · Germany (1) · Singapore (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Andrea Botticelli (1) · Marc Fellous, MD (1) · Paolo Marchetti (1) · Zachariah DeFilipp, MD (1)
PMID 38485149, PMID 39365992, PMID 40543428, PMID 40932470, PMID 41023484, PMID 41740031, PMID 41963505
2018 (1)